Latest research progress on Ribociclib

It is understood that the combination of Ribociclib (Ribociclib) and endocrine therapy has been shown to have a significant survival advantage for women with metastatic, hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. The same combination also showed benefit in early-stage HR+/HER2 breast tumors as of June 2023. demonstrated a significant reduction in the risk of recurrence, defined as an improvement in invasive disease-free survival in patients with high-risk, node-positive and node-negative hormone receptor-positive, HER2-negative early-stage breast cancer.

The new results come froman interim analysis of the phase 3 randomized NATALE trial, which compared maintenance therapy with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor reboxiclib plus endocrine therapy with an aromatase inhibitor with endocrine therapy alone. At a median follow-up of 27.7 months, the 3-year invasive disease-free survival (IDFS) rate was 90.4% for patients who received the combination therapy compared with 87.1% for those who received endocrine therapy alone.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.